A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg

Adequate organ function determined within 3 weeks of treatment initiation, defined as follows: Hemoglobin >= 8.0 g/dL; Absolute neutrophil count >= 1,000/mm^3 (1.0 x 10^9/L); Platelet count >= 50,000/mm^3 (50 x 10^9/L); Serum bilirubin <= 1.5 x ULN OR direct bilirubin <= ULN for a patient with total bilirubin level > 1.5 x ULN Aspartate aminotransferase (AST) <= 2.5 x ULN OR <= 5 x ULN for patients with liver metastases; Alanine aminotransferase (ALT) <= 2.5 x ULN OR <= 5 x ULN for patients with liver metastases; Alkaline phosphatase < 5 x ULN; Serum creatinine <= 1.5 x ULN or a measured or calculated creatinine clearance >= 60 mL/min for a patient with creatinine levels > 1.5 x institutional ULN (Note: Creatinine clearance need not be determined if the baseline serum creatinine is within normal limits. GFR can also be used in place of creatinine or CrCl); INR or PT <= 1.5 X ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants; aPTT <= 1.5 x ULN unless subject is receiving anticoagulant therapy as long as PT and PTT is within therapeutic range of intended use of anticoagulants